Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 3/14/13  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Ignacio Faus

Wrong Dr. Ignacio Faus?

Chief Executive Officer

Phone: +34 *********
Local Address: Palau-solita i Plegamans, Spain
Company Description: Palau Pharma S.A. ("Palau") is a product-driven biopharmaceutical company that is applying its expertise to the discovery and development of innovative...   more
Background

Employment History

Board Memberships and Affiliations

Education

  • degree , Business Administration ( Finance
    Deusto University
48 Total References
Web References
PALAU PHARMA
www.palaupharma.com, 14 Mar 2013 [cached]
Ignacio Faus
Chief Executive Officer (CEO)
EBE - European Biopharmaceutical Enterprises
www.ebe-biopharma.org, 28 Nov 2012 [cached]
Dr. Ignacio Faus Board Member CEO Palau Pharma
Ignacio ...
www.permira.com, 23 Sept 2009 [cached]
Ignacio Faus Permira - Our People
...
Ignacio Faus Position: Investment Professional Office: Menlo Park Sector Focus: TMT Address: Permira Advisers L.L.C. 64 Willow Place, Suite 101 Menlo Park, CA 94025 United States Tel: +1 650 681 4707 Fax: +1 650 853 0180 Email:ignacio.faus@permira.com
Ignacio joined the Madrid office in 2005 and relocated to the Menlo Park office in 2008. e works across sectors, with a particular focus on the TMT sector. gnacio has worked on a number of transactions including Cortefiel, NDS and Telepizza.
Prior to joining Permira, Ignacio spent 10 years at KPMG in the Audit and Transaction Services departments of Madrid and Manchester.
Ignacio has a degree in Business Administration (Finance) from the Deusto University, Spain and is a Chartered Accountant.
PALAU PHARMA
www.palaupharma.com, 30 July 2012 [cached]
Commenting on the deal, Ignacio Faus, CEO of Palau Pharma said: "The execution of this transaction will allow Palau Pharma to maximize the potential of UR-63325 in a new set of indications with high unmet medical needs.
PALAU PHARMA
www.palaupharma.com, 8 June 2012 [cached]
Commenting on the deal, Ignacio Faus, CEO of Palau Pharma said: "This transaction validates, once more, the scientific and business strategy of Palau, focused on developing novel medicines for the treatment of high-prevalence diseases with an inflammatory and autoimmune component.
Other People with the name "Faus":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304